Clinical Trials Browser

Phase 3 × Neoplasms × Rituximab × Clear all

NCT06191744 2026-05-06

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05409066 2025-07-28

EPCORE FL-1

Phase 3 Active not recruiting

549 enrolled 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05578976 2025-01-23

EPCORE DLBCL-2

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01788020 2024-05-13

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Phase 3 Completed

Waldenstrom Macroglobulinemia, Neoplasms

NCT02366663 2018-03-12

SPINOZA

Phase 3 Terminated

3 enrolled 8 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01014208 2015-08-07

ORCHARRD

Phase 3 Completed

447 enrolled 21 charts

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse